Understanding the Impact of Salvage Radiation on Prostate Cancer Outcomes

Strategic Insights -

Researchers at the Mayo Clinic have investigated the effect of salvage radiation therapy (SRT) on the long-term natural history of biochemical recurrence (BCR) in patients with prostate cancer after radical prostatectomy. The study examined the outcomes of 6881 patients with BCR, with 2109 receiving SRT and 4772 undergoing observation alone. The researchers found that SRT significantly reduced the risk of metastases at 5 and 15 years, with a median follow-up of 10.2 years. However, careful patient selection and shared decision making are recommended to limit overtreatment and side effects.

Key Takeaways:

  • The study analyzed the outcomes of 6881 patients with biochemical recurrence after radical prostatectomy, with 2109 receiving salvage radiation therapy (SRT) and 4772 undergoing observation alone.
  • SRT significantly reduced the risk of metastases at 5 and 15 years, with a median follow-up of 10.2 years.
  • The median PSA at the time of SRT was 0.50 ng/mL.
  • After 1:1 propensity score matching (2109 patients per cohort), SRT significantly reduced the risk of metastases at 5 (12.7% vs. 19.3%, p < 0.001).
  • The number needed to treat (NNT) with SRT to prevent progression was derived at 5 and 15 years.
  • Careful patient selection and shared decision making are recommended to limit overtreatment and side effects.
  • The study's findings provide valuable insights for clinicians and patients considering SRT for biochemical recurrence after prostatectomy.

Statistics:

  • 6881 patients with biochemical recurrence after radical prostatectomy were included in the study.
  • 2109 patients received salvage radiation therapy (SRT).
  • 4772 patients underwent observation alone after biochemical recurrence.
  • 1147 patients developed metastases at a median follow-up of 10.2 years.
  • SRT significantly reduced the risk of metastases at 5 years (12.7% vs. 19.3%, p < 0.001).
  • SRT significantly reduced the risk of metastases at 15 years (26.3% vs. 37.4%, p < 0.001).
  • The median PSA at the time of SRT was 0.50 ng/mL.

Sources:

  • Cancer Medicine, 2025;14(13).
  • Wiley, 111 River St, Hoboken 07030-5774, NJ, USA (www.wiley.com).
  • Mayo Clinic, Dept. of Urology, Rochester, MN 55905, United States.
  • Vidit Sharma, Mayo Clinic, Dept. of Urology, Rochester, MN 55905, United States.